The Goa based leading pharma company Cosme Farma Laboratories Ltd (CFLL) is planning to set up its new export oriented manufacturing unit with a total investment of Rs 70 crore. The company has not yet finalised the location.
Cosme Farma has two WHO cGMP certified manufacturing facilities for oral liquid and parenterals. The company has more than 110 dossiers, which is registered in different unregulated markets. Further, almost 150 dossiers are in the process of registration in different countries. The company manufactures products for Glaxo, Serum Institute of India and E Merck in its manufacturing facility. It also manufactures its products at different loan licence locations.
Speaking to Pharmabiz, Andre Menezes, director marketing said, "We are planning to set up new manufacturing unit by the mid of 2009. We have seen three sites in Goa, Karnataka and Hubli but not yet finalised the location. We are targeting this facility for the export activity. For the financial year 2007 -08, we are expecting to Rs 100 lakh from exports business".
The company has a well equipped R&D facility at Ponda. It is recognised by the Department of Scientific and Industrial Research. The department is housed with Analytical Research Laboratory to meet the domestic and international quality standards, certified by Science and Technology. Its R&D has always been a focus area for orthopaedic, gastrology and paediatric. CFLL has added approximately 250 people in the field force for the year 2007 - 08.
Menezes said, "While we do not do any new drug discovery research in R&D, we are focused in researching and developing new drug delivery systems, researching new indication for products in our current portfolio, adaptation of novel technologies, like Nanotech, for the current and future products, improving manufacturing methods to reduce costs of drugs to patients, and finding new ethical and rational combinations.
Currently, the company has at least 40 new products in the pipeline and in the next 12 months, all these products will be launched in Indian market. Many of these products are focused in the specialties of existing therapeutic areas. Besides, there are some other products, which can be used to extend the company's reach in covered markets. Some significant development work is also on in herbal medicines and cosmetology products. Some new products have been added to company's portfolios that are relevant, Menezes said.